ORGS

Healthcare Biotechnology

Orgenesis Inc.

$0.58

+0.03 +5.45% today

Price History

Not enough data

Key Stats

Market Cap

5.68M

Avg Volume

471

EPS

-$11.44

52W High

$1.00

52W Low

$0.00

Div. Yield

0.0%

Valuation

Forward P/E

0.95

P/B Ratio

-0.08

P/S Ratio

5.49

EV/EBITDA

-0.95

EV/Revenue

21.98

Margins

Gross Margin (86.3%)

Operating Margin (2196.3%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

215.5%

Return on Assets

(204.5%)

Liquidity & Leverage

Current Ratio

0.03

Quick Ratio

0.00

Total Cash

204,000

Total Debt

17.30M

About

Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

orgenesis.com